TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Highlights from ESMO 2019
Blood first assay screening in patients with ALK positive NSCLC
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Role of molecular diagnostics in prostate cancer
Melanoma highlights from ESMO 2019
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma
Comment: Targeted therapy ivosidenib in cholangiocarcinoma
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA